Therapy with an investigative JAK1/TYK2 inhibitor led to remission in one-third of participants with difficult-to-treat rheumatoid arthritis (RA).
January 29,2023Highlightll Pharmaceutical TLL-018 Achieved Breakthrough Results in a Phase II Trial for Rheumatoid ArthritisRead More
January 19,2023Vial Announces Enrollment of First Patient in Phase II Clinical Trial TLL018- 205 for the Treatment of Plaque Psoriasis Sponsored by Highlightll PharmaceuticalRead More
July 02,2021HANGZHOU HIGHLIGHTLL: TWICE THE TARGET, HOLD THE TOXSutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer compound against the same targets to treat a broad range of autoimmune diseases. Both compounds would need to find a foothold in a crowded marketplace.Read More